Status:

COMPLETED

Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease

Lead Sponsor:

Oslo University Hospital

Conditions:

Celiac Disease

Eligibility:

All Genders

18-80 years

Phase:

PHASE1

PHASE2

Brief Summary

The investigators will see if the drug teriflunomide (which is in use in other immune disorder (multiple sclerosis)) can inhibit the immune activation in celiac disease patients during a 3 day gluten ...

Detailed Description

This is a controlled, double-blind, randomised, singlecentre, placebo-controlled, phase IIa proof-of-concept study on effects of the drug on activation and efflux of gluten specific T cells using HLA-...

Eligibility Criteria

Inclusion

  • Patient aged 18-80
  • Willingness to comply with the study procedures and having signed informed, written consent
  • Previous diagnosis of coeliac disease according to established guidelines based on positive serology (Endomysium test, IgA-TG2 and/or IgGDGP) and a duodenal biopsy showing villous atrophy graded as Marsh 3
  • Positive gene test for HLA-DQ2.5
  • Adherence to gluten-free diet

Exclusion

  • Known intolerance to ingredients of teriflunomide or placebo tablets
  • Known intolerance to gluten challenge
  • Known intolerance to cholestyramine
  • Duration of gluten free diet shorter than six months
  • Positive serology (IgA-TG2 below upper level of normal) at screening visit
  • Pregnancy or breast-feeding
  • Not willing to comply with proper pregnancy control (in females)
  • Concomitant medication that interferes with immune activation (e.g. steroids, calcineurin inhibitors, biological treatment for inflammatory bowel disease or other immune disorders, further list is given below)
  • Any other medical condition that in the opinion of the principal investigator makes the individual unsuitable for participation

Key Trial Info

Start Date :

April 16 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 31 2023

Estimated Enrollment :

15 Patients enrolled

Trial Details

Trial ID

NCT04806737

Start Date

April 16 2021

End Date

December 31 2023

Last Update

May 16 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dept of Gastroenterology

Oslo, Oslo County, Norway, 0881

Teriflunomide vs. Placebo During Gluten Challenge in Celiac Disease | DecenTrialz